GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
brief summary
This phase 1 study evaluates the safety, efficacy, and biological activity of GB-5267 in patients with platinum-resistant ovarian cancer.
detailed description
PRIMARY OBJECTIVE:
* To evaluate the safety and tolerability of GB-5267 in patient with platinum resistant ovarian cancer * To determine the maximum tolerated dose (MTD).
SECONDARY OBJECTIVE:
\- To assess the anti-tumor activity of GB-5267
This is a dose escalation study of GB-5267 In Cohort 1 Patients receive IV only infusion. Dose escalation continues until Maximum tolerated dose (MTD) is established. Once the MTD has been established Cohort B (Dose expansion with Combined IV and IP Infusion) is intended to assess whether this approach enhances local antitumor effects in the peritoneal cavity.
official title
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of GB-5267, an IL-18 Armored CAR T Cell Product Targeting MUC16, in Patients With Platinum-Resistant Ovarian Cancer